Eulambius M. Mlugu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eulambius M. Mlugu has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Appolinary Kamuhabwa
Muhimbili University of Health and Allied Sciences, 9 United Nations Road, Upanga West P O Box 65001, Dar es salaam, Tanzania
1 shared publication - Eleni Aklillu
Department of Global Public Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
1 shared publication - Omary Minzi
Department of Clinical Pharmacy and Pharmacology, School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar es Salaam P.O. Box 65013, Tanzania
1 shared publication
Latest Publications
- Open Access
- 23 April 2021
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 110 (6) , 1478-1489
Effectiveness of Intermittent Preventive Treatment With Dihydroartemisinin‐Piperaqunine Against Malaria in Pregnancy in Tanzania: A Randomized Controlled Trial
Intermittent preventive treatment in pregnancy with sulfadoxine‐pyrimethamine (IPTp‐SP) to prevent malaria and adverse birth outcomes is threatened by Plasmodium falciparum resistance to sulfadoxine‐pyrimethamine. We investigated the effectiveness of intermittent preventive treatment in pregnancy with monthly dihydroartemisinin‐piperaquine (IPTp‐DHP) as an alternative option to IPTp‐SP. A total of 956 malaria‐free (malaria rapid diagnostic test (MRDT) negative) pregnant women from moderate malaria transmission areas in Tanzania were enrolled and randomized to receive monthly IPTp‐DHP (n = 478) or IPTp‐SP (n = 478) and followed for maternal and birth outcomes. The primary outcome was the prevalence of histopathologically confirmed placental malaria (active or past infection). Secondary outcomes were overall malaria at delivery, symptomatic‐malaria, parasitemia during pregnancy, and adverse birth outcomes as a composite of spontaneous‐abortion, premature birth, stillbirth, and low birth weight (LBW) fetal anemia. Outcome differences between treatment groups were expressed as the protective efficacy (PE), defined as 1‐prevalence ratios or 1‐incidence rate ratio. The prevalence of histopathologically confirmed placental malaria was significantly lower in IPTp‐DHP (2.5%, 12/478) than IPTp‐SP (8.2%, 39/478); PE = 69% (95% confidence interval (CI): 42–84, P < 0.001). The prevalence of maternal malaria at delivery was significantly lower in IPTp‐DHP (8.2%) than IPTp‐SP (18.2%, P < 0.001). The incidence per person‐years at risk for symptomatic‐malaria (0.02 vs. 0.12, P = 0.002) and parasitemia during pregnancy (0.28 vs. 0.67, P < 0.001) were significantly lower in the IPTp‐DHP group than in the IPTp‐SP group. The prevalence of any adverse birth outcomes (composite) was not significantly (P = 0.06) different between IPTp‐DHP (17.9%) and IPTp‐SP (23.8%). However, the prevalence of LBW (4.6% vs. 9.6%, P = 0.003) was significantly lower in IPTp‐DHP compared with IPTp‐SP. We report superior protective efficacy of monthly IPTp‐DHP against malaria in pregnancy and LBW than IPTp‐SP.
- 23 April 2021
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 110 (6) , 1478-1489
Open AccessEffectiveness of Intermittent Preventive Treatment With Dihydroartemisinin‐Piperaqunine Against Malaria in Pregnancy in Tanzania: A Randomized Controlled Trial
Intermittent preventive treatment in pregnancy with sulfadoxine‐pyrimethamine (IPTp‐SP) to prevent malaria and adverse birth outcomes is threatened by Plasmodium falciparum resistance to sulfadoxine‐pyrimethamine. We investigated the effectiveness of intermittent preventive treatment in pregnancy with monthly dihydroartemisinin‐piperaquine (IPTp‐DHP) as an alternative option to IPTp‐SP. A total of 956 malaria‐free (malaria rapid diagnostic test (MRDT) negative) pregnant women from moderate malaria transmission areas in Tanzania were enrolled and randomized to receive monthly IPTp‐DHP (n = 478) or IPTp‐SP (n = 478) and followed for maternal and birth outcomes. The primary outcome was the prevalence of histopathologically confirmed placental malaria (active or past infection). Secondary outcomes were overall malaria at delivery, symptomatic‐malaria, parasitemia during pregnancy, and adverse birth outcomes as a composite of spontaneous‐abortion, premature birth, stillbirth, and low birth weight (LBW) fetal anemia. Outcome differences between treatment groups were expressed as the protective efficacy (PE), defined as 1‐prevalence ratios or 1‐incidence rate ratio. The prevalence of histopathologically confirmed placental malaria was significantly lower in IPTp‐DHP (2.5%, 12/478) than IPTp‐SP (8.2%, 39/478); PE = 69% (95% confidence interval (CI): 42–84, P < 0.001). The prevalence of maternal malaria at delivery was significantly lower in IPTp‐DHP (8.2%) than IPTp‐SP (18.2%, P < 0.001). The incidence per person‐years at risk for symptomatic‐malaria (0.02 vs. 0.12, P = 0.002) and parasitemia during pregnancy (0.28 vs. 0.67, P < 0.001) were significantly lower in the IPTp‐DHP group than in the IPTp‐SP group. The prevalence of any adverse birth outcomes (composite) was not significantly (P = 0.06) different between IPTp‐DHP (17.9%) and IPTp‐SP (23.8%). However, the prevalence of LBW (4.6% vs. 9.6%, P = 0.003) was significantly lower in IPTp‐DHP compared with IPTp‐SP. We report superior protective efficacy of monthly IPTp‐DHP against malaria in pregnancy and LBW than IPTp‐SP.